Statement: All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.
Primary_evidence: Outcome Measurement:    Percentage of Progression Free Participants After 16 Weeks of Treatment   Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline, at 2 consecutive examinations; occurrence of disease-related skeletal events. If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator, they were considered as having PD.   Time frame: 16 weeks Results 1:    Arm/Group Title: Afatinib 50 mg With Letrozole   Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression.   Overall Number of Participants Analyzed: 7   Measure Type: Number   Unit of Measure: Percentage of participants  28.57        (3.67 to 70.96) Results 2:    Arm/Group Title: Afatinib 40 mg With Letrozole   Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression.   Overall Number of Participants Analyzed: 13   Measure Type: Number   Unit of Measure: Percentage of participants  0.00        (0.00 to 24.71)